A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY SCARDA Chief Sees First 5 Years as Critical, Japan-Made mRNA Jabs as Initial Work
April 19, 2022
-
REGULATORY Japan Approves Novavax’s COVID-19 Vaccine; Distribution to Start in Late May
April 19, 2022
-
REGULATORY Novavax COVID-19 Vaccine Clears MHLW Panel, Approval Expected Soon
April 19, 2022
-
COMMENTARY Ukraine War Sheds Light on Vulnerabilities in Pharmaceutical Supply Chains in Emergencies
April 19, 2022
-
REGULATORY Emergency Approval Plan Clears Lower House Panel; Opposition Bills Rejected, but Some Ideas Make It into Resolution
April 18, 2022
-
BUSINESS Bayer Yakuhin Sees 2021 Sales Skid 0.6% but Still Reach Target, Retains Spot in Top 10
April 15, 2022
-
BUSINESS Lumakras Nears Japan Market, Amgen Eyes Simultaneous Launch with US for Next 5 Oncology Drugs: EVP
April 14, 2022
-
REGULATORY Chuikyo OKs Listing of 8 Drugs on April 20; Vyvgart, Lumakras, and More
April 13, 2022
-
REGULATORY Vyvgart, Pivlaz to Be 1st to Face Zero Premium Rule for Low Cost Disclosures
April 12, 2022
-
REGULATORY Japan Cancels Purchase of 40 Million AstraZeneca Shots: Official
April 12, 2022
-
BUSINESS Astellas, GSK, 2 Other Firms Log 10%-Plus Drop in Workforce: Jiho Poll
April 11, 2022
-
REGULATORY MHLW Set to Boost Recognition of Reporting System for Improper Drug Promotions
April 8, 2022
-
BUSINESS New Grad Hiring Down 4.4% in Spring 2022, Downtrend for Sales Reps Continues: Poll
April 7, 2022
-
BUSINESS Jardiance Now Allowed for Use in HFpEF Patients: Label Update
April 7, 2022
-
BUSINESS Jardiance, Ofev Drive Up Boehringer’s Japan Sales in 2021
April 6, 2022
-
BUSINESS Pfizer Tops 2021 Global Pharma Ranking on Vaccine Boon: Jiho Tally
April 6, 2022
-
REGULATORY SCARDA to Create “Safe and Secure Vaccines” as Command Tower: Chief
April 5, 2022
-
ORGANIZATION JPMA Chief Sees Free Pricing Proposal as Catalyst for Active Reform Debate
April 5, 2022
-
REGULATORY Novavax’s COVID-19 Vaccine Up for PAFSC Review on Regular Pathway
April 5, 2022
-
ORGANIZATION Policy Veterans’ Group Proposes Free Pricing, Chuikyo Re-Pricing Few Years Later
April 4, 2022
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…